anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention belongs to the technical field of biology, relates to a new gene recombinant anti-tumor invasion and metastasis drug and concretely relates to a recombinant urokinase segment and a plasminogen activator inhibitor-2 type mutant fusion protein. The present invention uses a PCR method to amplify a fusion protein gene cDNA. A parasitifer bacterium is converted after the fusion protein gene cDNA is cloned onto an expression vector to obtain a fusion gene expression plasmid, and methanol or temperature induces the fusion protein to be expressed. An expression product is obtained after the infusion protein is purified, and the purity reaches 95%. An experiment verifies that the fusion protein of the present invention has the immunogenicity of PAI-2 and uPA, and therefore, the fusion protein not only can inhibit the serine proteinase activity of uPA but also can be competitive with the uPA to combine uPAR. An extrasomatic invasion model test and a nude mouse tumor metastasis model test prove that the fusion protein has the obvious functions of inhibiting the growth and the invasion and metastasis of tumor cells.
The present invention relates generally to a method of blunting the postprandial glycemic response to a meal by feeding an acid controlled induced viscosity fiber system. The first component of the induced viscosity fiber system is anionic soluble fiber. The second component of the induced viscosity fiber system is water-insoluble, acid-soluble multivalent cations. The fiber system will typically be incorporated into a meal replacement nutritional. The present invention also refers to a method of delivering soluble fiber to diabetics and to persons needing to lose weight. Additionally, the invention refers to a method of promoting the feeling of fullness and satiety by feeding a nutritional product containing the induced viscosity fiber system.
Heart failure with preserved ejection fraction (HFpEF) is a syndrome characterized by impaired cardiovascular reserve in which therapeutic options are scarce. Our aim was to evaluate the inodilator levosimendan in the ZSF1 obese rat model of HFpEF. Twenty-week-old male Wistar-Kyoto (WKY), ZSF1 lean (ZSF1 Ln) and ZSF1 obese rats chronically treated for 6-weeks with either levosimendan (1 mg/kg/day, ZSF1 Ob + Levo) or vehicle (ZSF1 Ob + Veh) underwent peak-effort testing, pressure-volume (PV) haemodynamic evaluation and echocardiography (n = 7 each). Samples were collected for histology and western blotting. In obese rats, skinned and intact left ventricular (LV) cardiomyocytes underwent in vitro functional evaluation. Seven additional ZSF1 obese rats underwent PV evaluation to assess acute levosimendan effects (10 μg/kg + 0.1 μg/kg/min). ZSF1 Ob + Veh presented all hallmarks of HFpEF, namely effort intolerance, elevated end-diastolic pressures and reduced diastolic compliance as well as increased LV mass and left atrial area, cardiomyocyte hypertrophy and increased interstitial fibrosis. Levosimendan decreased systemic arterial pressures, raised cardiac index, and enhanced LV relaxation and diastolic compliance in both acute and chronic experiments. ZSF1 Ob + Levo showed pronounced attenuation of hypertrophy and interstitial fibrosis alongside increased effort tolerance (endured workload raised 38 %) and maximum O2 consumption. Skinned cardiomyocytes from ZSF 1 Ob + Levo showed a downward shift in sarcomere length-passive tension relationship and intact cardiomyocytes showed decreased diastolic Ca2+ levels and enhanced Ca2+ sensitivity. On molecular grounds, levosimendan enhanced phosphorylation of phospholamban and mammalian target of rapamycin. The observed effects encourage future clinical trials with levosimendan in a broad population of HFpEF patients.
Cervical cancer affects thousands of women globally with recurring high-risk HPV infections being at the centre of cervical pathology. Oncological treatment strategies are continually challenged by both chemoresistance and metastasis within patients. Although both work hand-in-hand, targeting their individual mechanisms could prove highly beneficial for treatment outcomes. Such targets include the metastatic-promoting stem cell marker, CD44, which is abundant in cervical cancer cells and is common to both chemoresistance and metastatic mechanisms. Seeing that many existing advanced-stage cervical cancer treatment regimes, such as platinum-based chemotherapy regimens, remain limited and are rarely curative, alternative treatment options within the field of immunology are being considered. The use of immune checkpoint inhibition therapy, which targets immune checkpoints, CTLA-4 and PD-1/PD-L1, has shown promise as an alternate standard of care for patients suffering from advanced-stage cervical cancer. Therefore, this review aims to assess whether immune checkpoint inhibition can mitigate the pathological effects of CD44-induced EMT, metastasis, and chemoresistance in cervical cancer patients.
This study addresses the unmet needs of female primary informal caregivers of youth with spinal cord injury. A one-group pre-post treatment design will be used. Consented caregivers will receive coaching via face-to-face or via the phone. Each caregiver will participate in up to 10 coaching sessions. Each coaching session will last up to 90 minutes. Coaching sessions will be audiorecorded and transcribed verbatim. Outcomes of coaching on caregivers' self-identified goals will be assessed using the Canadian Occupational Performance Measure.
DREAM is a behavioral treatment for diabetes mellitus (DM), as well as a secondary prevention strategy for dementia. DREAM acts to reinforce DM self-care and address negative beliefs about medications and physicians, which compromise glycemic control in African Americans (AAs). In DREAM, race-concordant community health workers (CHWs) will: 1) deliver in-home DM education tailored to AAs with MCI; 2) use action plans to reinforce diabetes self-care; 3) facilitate telehealth visits with a DM nurse educator to improve DM self-care and address participants' health beliefs; and 4) increase primary care physicians' (PCP) awareness of participants' cognitive deficits and health beliefs to optimize treatment of DM. .
The topical preparation contains only 500mg of cannabinoids per ounce. The other ingredients are the same in both arms.
OBJECTIVE: Negative body image is an increasingly important factor in chronic pain disorders; particularly because the two conditions mutually influence each other. Our study examines body-image-related attitudes and comorbid psychic symptoms in patients with chronic pain disorders.
METHODS AND MEASURES: 188 patients with chronic pain answered the Dresden body image questionnaire (DKB-35), the Hospital Anxiety and Depression Scale (HADS) and the Beck's Depression Inventory (BDI).
RESULTS: The mean values of the DKB-35 subscales range between 2.24 und 3.29. The subscale "vitality" has the lowest mean value. BDI and HADS correlated significantly with the DKB-35 subscales. The subscale "body-acceptance" intercorrelated high with the two subscales "vitality" and "self-aggrandizement".
CONCLUSION: Our findings verify that chronic pain is strongly associated with negative body image. The issues of vitality and psychological symptoms seem particularly central in this complex interaction. The biopsycho-social model and the avoidance-endurance approach to chronic pain offer important ideas for explanation and treatment.
Children of families who will be randomized in Group CP will first take part in the individualized child training program. After the completion of the child training program and the assessment (Time 2 assessment), parents will take part in the behavioral parent training program.
Aging-associated hepatic fatty acid (FA) oxidation dysfunction contributes to impaired adaptive thermogenesis. 5-Heptadecylresorcinol (AR-C17) is a prominent functional component of whole wheat and rye, and has been demonstrated to improve the thermogenic capacity of aged mice via the regulation of Sirt3. However, the effect of AR-C17 on aging-associated hepatic FA oxidation dysfunction remains unclear. Here, 18-month-old C57BL/6J mice were orally administered with AR-C17 at a dose of 150 mg/kg/day for 8 weeks. Systemic glucose and lipid metabolism, hepatic FA oxidation, and the lipolysis of white adipose tissues (WAT) were measured. The results showed that AR-C17 improved the hepatic FA oxidation, and especially acylcarnitine metabolism, of aged mice during cold stimulation, with the enhancement of systemic glucose and lipid metabolism. Meanwhile, AR-C17 improved the WAT lipolysis of aged mice, promoting hepatic acylcarnitine production. Furthermore, the adipose-specific Sirt3 knockout mice were used to investigate and verify the regulation mechanism of AR-C17 on aging-associated hepatic FA oxidation dysfunction. The results showed that AR-C17 failed to improve the WAT lipolysis and hepatic FA oxidation of aged mice in the absence of adipose Sirt3, indicating that AR-C17 might indirectly influence hepatic FA oxidation via regulating WAT Sirt3. Our findings suggest that AR-C17 might improve aging-associated hepatic FA oxidation dysfunction via regulating adipose Sirt3.
Inflammatory Bowel Disease (IBD) is a chronic relapsing-remitting disease with a remarkable increase in incidence worldwide and a substantial disease burden. Although the pathophysiology is not fully elucidated yet an aberrant immune reaction against the intestinal microbiota and the gut microbial dysbiosis have been identified to play a major role. The composition of gut microbiota in IBD patients is distinct from that of healthy individuals, with certain organisms predominating over others. Differences in the microbial dysbiosis have been also observed between Crohn Disease (CD) and Ulcerative Colitis (UC). A disruption of the microbiota's balance can lead to inflammation and intestinal damage. Microbiota composition in IBD can be affected both by endogenous (i.e., interaction with the immune system and intestinal epithelial cells) and exogenous (i.e., medications, surgery, diet) factors. The complex interplay between the gut microbiota and IBD is an area of great interest for understanding disease pathogenesis and developing new treatments. The purpose of this review is to summarize the latest evidence on the role of microbiota in IBD pathogenesis and to explore possible future areas of research.
ETHNOPHARMACOLOGICAL RELEVANCE: Mai Men Dong decoction (MMDD), a traditional Chinese medicine formula, is relevant to ethnopharmacology due to its constituents and therapeutic properties. The formula contains herbs like Ophiopogon japonicus (Thunb.) Ker Gawl., Pinellia ternata (Thunb.) Makino, Panax ginseng C.A.Mey, Glycyrrhiza uralensis Fisch, and Ziziphus jujuba Mill, Oryza sativa L., which have been used for centuries in Chinese medicine. These herbs provide a comprehensive approach to treating respiratory conditions by addressing dryness, cough, and phlegm. Ethnopharmacological studies have explored the scientific basis of these herbs and identified active compounds that contribute to their medicinal effects. The traditional usage of MMDD by different ethnic groups reflects their knowledge and experiences. Examining this formula contributes to the understanding and development of ethnopharmacology.
AIM OF THE STUDY: In the case of pulmonary fibrosis (PF), treating it can be challenging due to the limited treatment options available. This study aimed to assess the potential of MMDD as a treatment for PF by targeting macrophages and the PI3K/Akt/FOXO3a signaling pathway.
MATERIALS AND METHODS: In a mouse model of PF, we investigated the effects of MMDD on inflammation, fibrosis, and M2 macrophage infiltration in lung tissue. Additionally, we examined the modulation of pro-fibrotic factors and key proteins in the PI3K/Akt/FOXO3a pathway. In vitro experiments involved inducing M2-type macrophages and assessing the impact of MMDD on fibroblast activation and the PI3K/Akt/FOXO3a pathway.
RESULTS: Results demonstrated that MMDD improved weight, reduced inflammation, and inhibited M2 macrophage infiltration in mouse lung tissue. It downregulated pro-fibrotic factors, such as TGF-β1 and PDGF-RB, as well as markers of fibroblast activation. MMDD also exhibited regulatory effects on key proteins in the PI3K/Akt/FOXO3a signaling pathway.
CONCLUSIONS: MMDD inhibited M2 macrophage polarization and released profibrotic factors that inhibited pulmonary fibrosis. As a result, the PI3K/Akt/FOXO3a signaling pathway is suppressed. MMDD is proving to be a successful treatment for PF. However, further research is needed to validate its effectiveness in clinical practice.
Provided are liquid and powder grape extracts having elevated phenolic content. The extracts can be made from grape seeds, grape skins, or a combination thereof. In some instances, extracts may be blends of grape seed extracts and grape skin extracts. Methods of manufacturing such extracts area also provided. Such methods involve controlled temperature conditions to increase yield of phenolic compounds in the extracts. Methods of using the extraction for treating subjects are also provided, including treatment of cancer and end-organ damage relating to hypertension.
The present invention relates to a pharmaceutical composition representing a novel immunomodulating principle comprising bacterial endotoxin, fetal hemoglobin or more particularly a heme-free derivative or the gamma-chain thereof, and optionally, components which are present in the fetal liver in addition to HbF. The composition is delivered to humans in a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention it was surprisingly found that endotoxin and fetal hemoglobin partial structures display a pronounced synergistic biomedical activity. The biomedical effect of fetal hemoglobin and its partial structures is surprisingly not based on a classical hemoglobin function as an oxygen transporter but related to a modulation of endotoxin-mediated bioactivity. This biomedical activity is surprisingly also observed after oral application of the composition. The composition of the invention finds a variety of applications which have in common the stimulation of the immune system and the reversion in polarization of cytokines and chemokines from a Th2-directed response to a Th1-type response. The proposed applications would therefore include the treatment of allergic conditions, malignancies, chronic infections, autoimmune phenomena and age-related imbalances.
Daily oral administration of 400 mg celecoxib for 28 days. Positive control for LY3031207.
PURPOSE: A method for manufacturing a breast massage pack composition using Dioscorea japonica THUNB. and aloe is provided to improve skin whitening and skin moisturizing effects and to prevent skin trouble. CONSTITUTION: A method for manufacturing a breast massage pack composition using Dioscorea japonica THUNB. and aloe comprises: a washing step, a mucilage extracting step, a extraction mixing step, a drying step, a powder production step, a massage liquid preparation step, and a massage pack making step. Dioscorea japonica THUNB., aloe extract(mucin, juice), and glycerin are mixed in a ratio of 3:3:4. [Reference numerals] (AA) Washing step; (BB) Mucilage extracting step; (CC) Extract mixing step; (DD) Drying step; (EE) Powder preparation step; (FF) Massage liquid preparation step; (GG) Massage pack finishing step
Following completion of the DB phase, participants were asked to reconfirm their consent for participation in the LTSE phase (planned as a further 24 months) beginning at 5 or 10 mg OCA, based on the last treatment received during the DB phase. Doses up to 10 mg daily were evaluated. All participants received open-label OCA during the LTSE phase of the study.
The intervention under study will be the integrated care for cardiovascular risk management (CVRM), based on the Dutch CVRM guideline. Patients with a history of cardiovascular disease (CVD), a high cardiovascular risk (CVR) (\>10%) or use of antihypertensives or lipid lowering drugs are included in the program. Patients will be invited for an intake consultation, including a blood test, an interview, physical examination and estimation of the 10-years cardiovascular risk. If indicated, treatment with medication will be started and general lifestyle advises will be given. Patients can be referred to smoking cessation therapy, dietician and exercise programs or a physiotherapist. Patients will be controlled on a regular base to evaluate and adjust their personal goals.
PURPOSE:To prepare a therapeutic tape having high releasability of the drug component and the durability of the drug action, by adding a poor solvent and a drug to a solution of an acrylic polymer, stiring the mixture to coagulate and pulverize a part of the acrylic polymer to fine particles, and applying the resultant mixture to one surface of a substrate. CONSTITUTION:A solution of an acrylic polymer is added with its poor solvent (e.g. methanol, ethanol, etc.) and with a drug (preferably a water-soluble drug such as heparin sodium, sodium salicylate, etc.), and is stirred to convert a part of the acrylic polymer to coagulated fine particles. The resultant mixture of the polymer solution, coagulated fine particlesand drug is applied to one surface of a substrate and dried to obtain the objective tape or sheet for therapeutic use. The adhesive layer of the tape is composed of the homogeneous matrix of the acrylic polymer and the coagulated fine particles dispersed therein. It has high transcutaneous absorptivity, high resistance to the separation of the drug, and good preservability. It can be prepared by a simple process.
BACKGROUND: This case details a 44-year-old man with end-stage ischemic cardiomyopathy with refractory ventricular tachycardia (VT). The patient has a single-chamber implantable cardioverter-defibrillator, has had 2 VT ablations, and uses medication to manage his VT. Despite these interventions, he continued to have episodes of VT. The patient underwent stereotactic body radiation therapy (SBRT) to help reduce the burden of his VT. The patient received a dose of 25 Gy to his right inferior lateral region of the heart and a dose of 15 Gy to the inferior portion of the heart closer to the stomach. The patient followed up 1 month later and reported that his energy levels improved and that no arrhythmias had occurred since his SBRT treatment.
DISCUSSION: The options for treating end-stage VT are limited. However, a treatment option using SBRT has been introduced to reduce the VT burden in patients. Cardiac SBRT is a noninvasive outpatient procedure that, while still awaiting U.S. Food and Drug Administration approval, reduces arrhythmia episodes and offers favorable short-term benefits for patients who have not responded to traditional treatment modalities.
CONCLUSION: Cardiac SBRT is a novel treatment for VT in patients where standard treatments have failed. This case study demonstrates that SBRT effectively reduced arrhythmias in a patient with VT. The long-term clinical outcomes are not known, but the opportunity SBRT offers for treatment-refractory patients is favorable and should be considered.
BACKGROUND: Basal cell carcinoma (BCC) is the most common cutaneous malignancy. BCCs occur mainly in exposed areas, such as the face and scalp. Therefore, surgical resection with narrow margins is highly desirable. However, narrow margins may increase the risk of positive histopathological margins. Outcomes for such treatment might be unfavorable, but evidence for such a conclusion is lacking.
METHODS: Between April 2015 and November 2023, a total of 230 Japanese cases with BCC which underwent surgical resection with 2-mm, 3-mm, or 5-mm margins were followed in our hospital. We conducted a retrospective review that focused on the recurrence rate and histopathological margins.
RESULTS: Recurrence was recorded if the follow-up time was longer than 3 months. One of the 198 cases (0.5%) developed a recurrence. The mean lateral and deep histopathological margins were 2,525.4 μm (30.8-14,034.6 μm) and 3,409 μm (199.9-16,523.6 μm), respectively. Recurrence rate was associated with tumor size and clinical tumor border. However, histopathological margin was not associated with recurrence rate, even when it was less than 1,000 μm.
CONCLUSIONS: A narrow histopathological margin is acceptable for surgical resection of BCC in Japanese patients.
PURPOSE:To provide an antiphlogistic and analgesic medicine for external use, containing a non-steroidal and/or steroidal antiphlogistic and analgesic agent as the active component and phosphatidyl serine as the base component and excellent in percutaneous absorption, safety and stability. CONSTITUTION:This medicine contains a non-steroidal antiphlogistic and analgesic agent (e.g. indometacin or methyl salicylate) and/or a steroidal antiphlogistic and analgesic agent (e.g. hydrocortisone or prednisolone) as the active component in an amount of 0.001 to 5wt.% based on the whole external preparation and phosphatidyl serine as the base component in an amount of 0.1 to 30wt.%. Preparation is possible into a dosage form such as liquid, colloidal solution, emulsified lotion, hydrophilic cream, aqueous gel, hydrophobic cream or ointment. This medicine is applicable to inflammatory diseases such as eczema, lichen, ichthyosis, psoriasis, muscle pain and arthritics.
The invention discloses a chimeric human insulin and interleukin-10 double-gene co-expression recombinant plasmid vector and a construction method thereof. The method comprises the steps of (1) designing and synthesizing an Insulin-PGK-IL10 target gene. (2) Designing and synthesizing primers, amplifying target gene segments, and recovering enzyme digestion products after double enzyme digestion. (3) Plasmid vector pcDNA3.1 was digested simultaneously with XhoI and NotI. (4) And connecting the target gene fragment with the enzyme-digested pcDNA3.1. (5) And transforming the connected vector into competent bacteria, and coating a plate for screening to obtain the double-gene recombinant plasmid vector of the Insulin and the IL-10. The vector constructed by the invention is used for gene therapy of insulin-dependent diabetes mellitus.
Up to 350,000 patients above 65 years of age contact Danish emergency departments each year, and 40% of them have hyperosmolar dehydration (HD). HD often complicates other conditions. It increases mortality and morbidity, affects cognitive and physical function negatively and reduce the quality of life. This review recommends calculated serum osmolarity for the diagnosis of HD. The calculated osmolarity is based on blood samples already collected as standard. Improving the understanding, recognition, and treatment of HD can improve the outcome for older patients.